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ABSTRACT
Objective: Patients’ satisfaction with their medication or
medical device has been of increasing interest over the
past decade. This is reﬂective of the rise of the patient as
consumer and the desire of pharmaceutical and device
manufacturers to obtain feedback from the consumers
about their products. Satisfaction with medication is
more narrowly focused and should be distinguished from
other aspects of satisfaction. The purpose of this article is
to place the concept of patient satisfaction with medica-
tion in an appropriate theoretical context, to explore the
challenges of performing this research, and to offer rec-
ommendations for the basis of satisfaction claims.
Methods: We reviewed the literature on satisfaction with
medication or medical devices. We summarize and discuss
the background, conceptual issues, and theoretical justi-
ﬁcation for studying satisfaction with medication. We
offer examples of domains to be included and suggestions
on how to develop a psychometrically sound satisfaction
measure. We also address additional issues for consider-
ation.
Results: Medication satisfaction is a type of patient-
reported outcome, but is distinguished from other
patient-reported outcomes—speciﬁcally health-related
quality of life (HRQL) and self-reports of symptoms. The
Theory of Reasoned Action provides one theoretical jus-
tiﬁcation for the concept. The heuristic value of this the-
ory leads to implications regarding the relation between
satisfaction and adherence. In addition, the theory is con-
sistent with the need to focus on the patient’s beliefs and
values concerning the impact of taking his/her medica-
tion. Although the beliefs will differ according to the spe-
ciﬁc drug–disease combination, the beliefs can often be
categorized in several domains of satisfaction: symptom
relief/efﬁcacy, side effects, ease and convenience, impact
on HRQL, general satisfaction, and additional domains
speciﬁc to the given research question.
Conclusion: Patient satisfaction instruments should be
subjected to the same psychometrically rigorous stand-
ards and procedures as any other patient-reported out-
come and should also be subject to the same regulatory
standards as other patient-reported outcomes with
respect to advertising and promotion.
Keywords: adherence, patient-reported outcomes, satis-
faction, theory of reasoned action.
Background
The past few decades have witnessed increasing
interest in the issue of patient satisfaction with the
medical care they receive [1–10]. This interest
reﬂects the perspective that has developed over this
time of the patient as an active consumer of health-
care services rather than merely as a passive recipi-
ent of these services. Increased direct-to-consumer
(DTC) advertising over the past decade, three-tier
copays, and a dizzying array of information (and
misinformation) sources reinforce the patient-as-
consumer roles. And, like those responsible for pro-
viding many of life’s goods and services, including
automobile manufacturers, hotel chains, television
networks, and so on, providers of health-care serv-
ices have become increasingly interested in obtain-
ing feedback about their product from the primary
consumers of these products. In fact, assessment of
aspects of patient satisfaction with health care is a
component of the National Committee for Quality
Assurance (NCQA) recommended procedures for
assessing health plans [11,12].
It is quite natural, then, that concomitant with
the rise of the patient as consumer, pharmaceutical
and medical device manufacturers are asking ques-
tions such as: “Are our patients satisﬁed with our
medication?”; “How satisﬁed are our patients com-
pared to patients on our competitor’s product?”;
and so on. The demonstration of greater satisfac-
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tion with one product over another provides a com-
petitive marketing advantage, provided that such
claims are based in empirical data. Hence, over the
past few years, there has been an increasing interest
on the part of pharmaceutical ﬁrms in assessing
patient satisfaction with their medications. The pur-
pose of this article is to place the concept of patient
satisfaction with medication in an appropriate the-
oretical context, to explore the challenges of per-
forming research in patient satisfaction with
medication, and to offer recommendations for
assuring that satisfaction claims are based on the
results of studies designed and conducted in accord-
ance with principles used in other patient based
assessments. For purposes of this article, “satisfac-
tion with medication” will refer to satisfaction with
medication and/or medical devices.
Deﬁnitions and Distinctions
Satisfaction with Medication Versus Satisfaction
with other Aspects of Medical Care We deﬁne sat-
isfaction with medication as the patient’s evaluation
of the process of taking the medication and the out-
comes associated with the medication. This deﬁni-
tion is similar to that of Weaver et al. [10], in that it
emphasizes both process and results. We prefer to
use the term “satisfaction with medication” to the
more widely used term of treatment satisfaction, in
that the former focuses on the speciﬁc issue of
medication and the latter encompasses the entire
treatment experience. It is useful to think of a sat-
isfaction hierarchy (see Fig. 1). The broadest level of
the hierarchy is satisfaction with health-care deliv-
ery, which has been the basis for much of the recent
interest in treatment satisfaction [13–17]. Neverthe-
less, from the perspective of a researcher or practi-
tioner who is interested in patient evaluation of a
speciﬁc medication, assessment of patient satisfac-
tion with the entire delivery of health care is much
too broad. The latter will include a number of fac-
tors that go far beyond satisfaction with medica-
tion, such as access to appropriate medical staff on
a timely basis, perceived quality and responsiveness
of medical staff and quality of medical facilities, and
the patient’s own personal experience with respect
to the duration and severity of the disease and
expectations for receiving efﬁcacious and timely
medical care.
The middle level of Figure 1 represents treatment
satisfaction. Treatment satisfaction involves evalua-
tion of more than just the patient’s satisfaction with
the medication. It will include issues of physician–
patient interaction, recommendations by the physi-
cian that go beyond the speciﬁc medication (e.g.,
dietary restrictions, behavioral changes), and con-
comitant therapies (e.g., physical rehabilitation).
Assessment of treatment satisfaction as broadly
deﬁned here will result in a number of factors extra-
neous to the patient’s satisfaction with medication
for a researcher who is speciﬁcally interested in the
latter.
Finally, at the narrowest end of the hierarchy, we
have satisfaction with medication. Although not
denying the importance of the other aspects of sat-
isfaction, satisfaction with medication is the appro-
priate target of inquiry for a number of purposes
and should not be confused with the other levels of
the hierarchy. As we will see in this article, satisfac-
tion with medication is inﬂuenced by a variety of
factors, all of which are subject to assessment. To
the extent to which the treatment is focused entirely
on the medication, treatment satisfaction will
devolve to satisfaction with medication. Never-
theless, even in this case, there may be aspects of
treatment satisfaction (e.g., physician–patient inter-
actions, physician communication style) that will
result in treatment satisfaction not being identical
with satisfaction with medication.
Any level in Figure 1 can impact the other levels.
As a ﬁrst example, consider a patient who has been
prescribed a new medication for a chronic, debili-
tating disease. Satisfaction with medication, the top
level of the hierarchy in Figure 1, may positively dis-
pose the patient toward the entire health delivery
system (the bottom level of the hierarchy). Con-
versely, prescribing a drug that the patient believes
is less efﬁcacious because the preferred medication
is not on the formulary can negatively impact sat-
isfaction with the health delivery system. Similarly,Figure 1 Hierarchy of  levels of  health satisfaction.
_________
Satisfaction with
Medication 
(e.g., impact on symptoms; 
side effects—see text) 
_________≠Ø______________
Treatment Satisfaction 
(may include other procedures & therapies,
e.g., activity limitations, dietary restrictions) 
________________≠Ø____________________
Satisfaction with
Health Delivery System
(includes issues of accessibility, patient–physician 
interaction, perceived quality of staff and facilities)
_____________________________________________________
Broad 
Precise
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a physician’s communication style with the patient
inﬂuences the patient’s satisfaction with the health
plan [18,19], as well as with the medication [20].
This is an example of the middle level of the
Figure 1 inﬂuencing both the top and the bottom
levels. Nevertheless, the central lesson of Figure 1 is
that we need to match the level of satisfaction
assessed in a given study with the level that is most
appropriate for the study objective. Instruments
such as the Patient Satisfaction Questionnaire [21],
the Client Satisfaction Questionnaire [22], and the
Service Quality Instrument (SERVQUAL) [23],
while appropriate for assessing the bottom level of
the hierarchy, are far too broadly focused to assess
satisfaction with speciﬁc therapies, the target of the
present review.
Why Should We Measure Satisfaction with
Medication? Patient satisfaction is a legitimate
patient-reported outcome to consider for inclusion
in studies on medications for the following reasons:
First, we would expect satisfaction with medica-
tion to be related to patient adherence to prescrip-
tion regimens. Although drug adherence is an
important and complex medical issue [24–29],
there has been little research that empirically dem-
onstrates the link between medication satisfaction
and adherence. This deﬁciency reﬂects the general
lack of research involving patient satisfaction with
medication—many of the studies that assess satis-
faction along with adherence have focused on sat-
isfaction with care, rather than satisfaction with
medication. As implied by Figure 1, if our intent is
to determine the relationship between adherence to
a regimen for prescription of a medication, the
appropriate level of assessment of satisfaction is at
the level of satisfaction with medication, not satis-
faction with care or satisfaction with health deliv-
ery. In addition, the lack of empirical support for
the relation between adherence and satisfaction
with medication also reﬂects measurement difﬁ-
culty, both in measuring adherence and in ade-
quately measuring satisfaction with medication.
Typically, when satisfaction with medication has
been measured, the assessment involves a single
question assessing overall satisfaction. The study by
Shikiar et al. [8] is one of the few studies to focus
speciﬁcally on various aspects of dimension with
satisfaction and to subsequently [30] explore its
relation to adherence.
Second, detailed feedback about patient satisfac-
tion can be used in improving products. For exam-
ple, if it is found that lack of convenience of taking
the medication is a key factor resulting in decreased
satisfaction, the drug might be reformulated in a
way that results in a less frequent dosing require-
ment. If satisfaction is not measured, systematic
efforts cannot be made to improve it.
And ﬁnally, all other things being equal, we
would expect satisfaction to be related to patients’
preferences—and requests for speciﬁc medications.
In the case of a patient who has had the opportunity
to have tried several different medications, the one
with which he or she is most satisﬁed will likely be
the drug of choice. For patients who have not yet
had medication prescribed for their disease, the sit-
uation is a bit more complicated. Nonetheless,
patients’ expectations about being satisﬁed with a
drug can be shaped by a variety of information
sources, including DTC advertising.
When Is Satisfaction with Medication Worthwhile
to Assess? Despite the enthusiasm for assessing sat-
isfaction with medication, it is not always an appro-
priate endpoint. For example, in situations where a
medication is clearly the most efﬁcacious com-
pound, there is usually no need to expend the effort
to assess satisfaction with medication. Similarly,
where the comparator in a clinical trial is a placebo,
assessing satisfaction with medication as an end-
point in these trials might not be worth the effort in
many cases, especially if the drug will be competing
with existing medications. Another instance where
satisfaction with medication may not be worth
assessing is when the medication is only a small part
of a comprehensive treatment plan. In such
instances, patients may have a difﬁcult time discern-
ing the impact of the medication from the rest of the
treatment regimen.
Consider assessing patient satisfaction with med-
ication when:
• One medication offers offsetting advantages
and disadvantages relative to another in terms
of efﬁcacy and side effects.
• Medications of approximate equal efﬁcacy
have competing modes of administration or
other convenience factors (e.g., dosing
schedules).
• Medications of approximate equal efﬁcacy
have different side effect proﬁles.
• The medication plays a central role in the treat-
ment regimen.
• There are other unique situations where dem-
onstration of satisfaction with a medication rel-
ative to a comparator is considered to offer a
potential advantage with respect to adherence
issues or in marketing.
Satisfaction with Medication 207
Satisfaction with Medication Versus other Patient-
reported Outcomes Satisfaction with medication is
conceptually distinct from health-related quality of
life (HRQL), symptom assessment, functional sta-
tus, or any other patient-reported outcome that may
be assessed. Central to the selection of a patient-
reported outcome, should one be desired, is the
research question: What is the desired outcome of
the trial? If the hypothesis is that drug A will reduce
pain symptoms by 20% more than drug B, then
symptoms must be assessed. If an additional
hypothesis is that patients will be more satisﬁed on
drug A than B, then satisfaction with medication
must also be assessed. Satisfaction with medication
does not have to be assessed with other patient-
reported outcomes. Nevertheless, it generally is.
HRQL pertains to the impact of health on a per-
son’s physical, psychological, and social/occupa-
tional functioning and well-being [31]. Typically,
HRQL is based on the patient’s own assessment of
his/her status regarding these dimensions, using a
wide variety of generic and/or disease-speciﬁc
instruments (e.g., see Spilker [32] and McDowell
and Newell [33] for descriptions). Increasingly,
HRQL measures are being included as secondary or
primary outcomes in clinical trials [34]. HRQL
assessments typically result in a score for a patient
on each of the domains used in the HRQL instru-
ment (e.g., a “vitality” score of 70 on the SF-36 [35],
a psychosocial score of 65 on the Sickness Impact
Proﬁle [36], an HAQ score of 1.75 [37]). Note that
there is nothing inherently evaluative about the
scores resulting from assessments of HRQL.
Although most observers, including the patient him-
or herself, would agree that more vitality is better
than less vitality, or that more pain is worse than less
pain, the respective scores do not indicate the
patient’s evaluation of the HRQL, but only their sta-
tus on the respective dimension. Utility measures
(e.g., the Health Utility Index, the EuroQoL)
attempt to rectify this shortcoming by assessing the
desirability or preference associated with the partic-
ular HRQL status. Nevertheless, neither a measure
revealing the patient’s HRQL status nor a utility
score associated with that status reveal the patient’s
satisfaction with the medication vis-à-vis its role in
creating that HRQL status for the patient. As dis-
cussed later in this article, one important component
of medication satisfaction is the assessment of the
extent to which the medication is perceived to
impact HRQL, but that assessment is distinct from
the actual HRQL outcomes themselves.
Self-reports of symptoms deal with a patient’s
assessment of the presence/absence or the severity of
symptoms, usually obtained via standardized symp-
tom questionnaires. As with the case for assessing
HRQL, self-reports of symptoms will typically
result in a score for a patient on a given symptom or
symptom category (e.g., a depression symptom
score of 35 on the CES-D [38], a pain score of 1.5
on the Brief Pain Inventory [39]). As with the case
for HRQL scores, although most observers would
agree that less severe is better than more when it
comes to symptoms, there is nothing inherently
evaluative about these symptom scores. The symp-
tom score is distinct from the patient’s evaluation of
the medication’s impact on his/her symptoms.
Satisfaction with medication, on the other hand,
deals speciﬁcally with the evaluative aspect of the
patient’s experience with the medication. In accord
with our deﬁnition, that experience involves both
the process and the outcomes associated with the
medication. With respect to the outcomes associated
with a medication (e.g., symptom reduction,
changes in HRQL), the extent to which the patient
perceives the medication as positively impacting val-
ued outcomes should logically be related to the
patient’s evaluation of the medication—that is, his/
her satisfaction with the medication. Note that
under this conception of satisfaction, satisfaction
with medication is inﬂuenced by the outcomes of
treatment, especially HRQL and symptom status,
but it is not identical to these constructs. Another
way of thinking about the relationship among these
patient-reported outcomes is that HRQL and self-
reported symptoms represent patient reports of the
patient’s status on each of the constructs in question,
whereas satisfaction takes into account the extent to
which the patient values each of these status points,
as well as other factors that enter into determining
satisfaction, discussed later in this article.
Figure 2 demonstrates the conceptual relation-
ship among the patient-reported outcomes dis-
cussed in this section. At the top of Figure 2, we
assume treatment will include the medication of
interest as a major component. If not, then satisfac-
tion with medication would usually not be an out-
come worth assessing. Treatment is designed to
positively impact or prevent patients’ symptoms.
The extent of this impact can be measured by clin-
ical examination or patient assessment of symp-
toms. A patient’s satisfaction with medication will
be determined, in part, by the extent to which the
patient attributes the change in symptoms to the
action of the medication. If the patient believes the
medication has improved disease-related symptoms,
then all other things being equal, that treatment
medication should be positively evaluated. For
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example, consider a patient with chronic lower
back pain who has already tried physical therapy,
weight loss, and standard OTC drugs. If the physi-
cian now prescribes a pain medication, and the pain
symptoms are greatly improved, then the patient is
likely to attribute the improved health status to the
prescribed medication. If the patient had not previ-
ously tried physical therapy and weight reduction,
and the physician recommends both as well as pre-
scribing the pain medication and the pain symptoms
decrease substantially as a result of the medication,
the patient may not attribute the improvement
entirely to the drug. Although it is conceptually sim-
ple to design controlled experiments to tease out the
impact of the different aspects of the treatment, in
practice these types of tightly controlled experi-
ments will not usually take place for the sole pur-
pose of determining patient satisfaction. Hence, our
admonition that the medication should be a major
component of the treatment if the goal is to deter-
mine satisfaction with medication as opposed to the
more general treatment satisfaction.
Note that the medication impacts not only dis-
ease symptoms, but may also result in side effects
that the patient ﬁnds bothersome. Hence, to the
extent that the patient attributes negatively valued
side effects to the action of the drug, patient satis-
faction with medication should decrease. Therefore,
in assessing satisfaction with medication, it is
important to determine the patient’s satisfaction
with the action of the drug on his or her symptoms
and with the side effects of the drug. Ascertaining
patients’ satisfaction with the impact of the drug on
symptoms and side effects is different from assess-
ing symptoms and side effects directly and requires
a different set of questions.
Because symptoms and side effects owing to
medication are affected by medication, they in turn
inﬂuence HRQL and functional status. Wilson and
Cleary [40] discuss the complex relationships
among environmental and individual patient char-
acteristics, symptom and functional status, and
HRQL. Nevertheless, for the rather limited goal of
assessing satisfaction with medication, we believe
that assessment of environmental and many individ-
ual personality and motivational variables will
result in far greater complexity than is warranted in
many medication satisfaction studies. Nonetheless,
if a medication has an impact on HRQL or func-
tional status, it is important to assess the patient’s
satisfaction with this effect, even though it may
occur indirectly through the drug’s action on symp-
toms and side effects.
There are factors that may inﬂuence satisfaction
with medication that have little or nothing to do
with the perceived effect of the drug on symptoms,
HRQL, or functional status. These factors include
the ease and convenience with which a patient can
adhere to their medication. For example, the mode
of administration or medication storage require-
ments of a new medication may be more tolerable
than previous treatments. Patients would then be
more satisﬁed with this medication because it would
be easier to use. Other factors include the medica-
tion’s dosing schedule, the patient’s conﬁdence in his
or her ability to take the medication properly, or the
comfort level a patient feels with the amount of
information received on the medication from the
physician or other health-care provider. Although
these factors may have negligible impact on the
patient’s well-being, they may very well be a deter-
mining factor in satisfaction in cases where the drug
and its comparators have similar clinical efﬁcacy.
Figure 2 also conveys the concept that the
patient’s judgment of satisfaction with medication is
mediated by his or her expectations with respect to
the impact of the medication on symptom relief, on
side effects, and on HRQL and functionality. The
importance of expectations is described in more
detail in the next section.
Conceptual Issues: Theoretical Justiﬁcation 
and Domains of Satisfaction
Satisfaction as an Antecedent of  Adherence: The 
Theory of  Reasoned Action
In their review of the patient compliance literature,
Morris and Schulz [25] state: “More than 20 years
Figure 2 Depiction of  relation among different patient-reported
outcomes.
Expectations
TREATMENT 
(including 
Medication)
Symptoms, Side
Effects 
HRQL and 
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Satisfaction with
Medication 
Other Influences on 
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of research in the area of compliance has produced
very little consistent information on the factors
which can be correlated with noncompliant behav-
ior. Most of the variables examined are inconsist-
ently correlated with compliance and thus cannot
be used to predict compliant behavior adequately.”
Morris and Schulz [25,26] argue that the patient is
an active participant in the decision to comply or
not comply with a prescribed medical regimen and
that to better understand and predict compliance, it
is important to consider the patient’s perspective.
Adherence to a given medical regimen may be
related to an individual’s lifestyle, ﬁnancial options,
level of disease symptoms versus medication side
effects, and other factors. Thus, an understanding
of different aspects of a medication, such as clinical
(e.g., symptom relief, side effects), HRQL, and
ﬁnancial, should be given attention in the assess-
ment of treatment adherence.
There are several useful conceptual models to
assist us in gaining insight into satisfaction with
medication. We ﬁnd models that are consistent with
that of the admonition by Morris and Schultz [25]
to treat patients as active participants and decision
makers in the decision to take their medication [41]
to be most useful for our purposes. In particular, we
believe that the Theory of Reasoned Action (TRA)
[42–44] is a particularly useful heuristic for under-
standing satisfaction with medication and adher-
ence to treatment from the patient’s perspective, as
well as for linking adherence to satisfaction. It
should be noted that TRA has a long history of use
in both health and nonmedical-care-related phe-
nomena, including smoking [45], drinking [46],
contraceptive use [47], exercise behavior [48], vot-
ing [49], and wearing seat belts [50]. There have
also been some applications of TRA to the issue of
medical compliance [51–53]. Although it is not nec-
essary to invoke TRA to justify the assessment of
patient satisfaction with medication, TRA leads to
several important concepts that can be translated
into research on satisfaction with medication.
The TRA was developed explicitly to address the
issue of the relationship between attitudes and
behaviors. Hence, to glean useful insights from TRA,
we can consider satisfaction with medication to rep-
resent the patient’s “attitude” toward the medication
or, more speciﬁcally, the patient’s attitude toward
“taking the medication.” Both attitude and satisfac-
tion are constructs that deal primarily with the eval-
uative aspects of a person’s perception of an object;
hence, the substitution of one construct for another
for purposes of gleaning possible insights should not
be considered too far of a stretch with respect to
either construct. According to TRA, attitude toward
the behavior of taking one’s medication is deter-
mined by two elements: the person’s beliefs about the
outcomes of performing the behavior, weighted by
the evaluation of each of these outcomes [43]. Thus,
a person who believes that mostly positively valued
outcomes (e.g., cessation of symptoms, no side-
effects of drug, positive impact on lifestyle) will
result from engaging in the behavior of taking the
medication in the prescribed fashion will have a pos-
itive attitude toward their medication. Conversely, a
person who believes that more negative outcomes
(e.g., painful side effects, only modest reduction in
symptoms, a drug administration mode such as sub-
cutaneous injection that severely crimps one’s life-
style) result from taking the medication will have a
less positive attitude toward taking their medication.
It is important to keep in mind that the beliefs
under consideration are very speciﬁc to the act of
taking the medication (i.e., “If I take this drug for
my disease, then I will have . . .”). In this sense, they
serve as expectations about taking the drug—in
fact, TRA is an expectancy-value model. In this
way, TRA helps us to link expectations about a drug
to satisfaction. To the extent that one expects—or
believes—that positive outcomes will continue to
result from taking the medication, the more satisﬁed
that person should be. Should expectations not be
matched or exceeded—for example, the extent of
symptom relief was not as great or the side effects
were worse than expected—then we would expect
satisfaction with the medication to suffer. It is this
sense, then, that expectations are seen to mediate
judgments of satisfaction, as shown in Figure 2.
Note that a person’s expectations about the out-
comes of taking a medication can be formed and
inﬂuenced by a myriad of factors, as shown in the
right side of Figure 2. A person’s experience with
the speciﬁc drug or with the class of drugs will often
be the greatest inﬂuence on these beliefs (“This
migraine medication has resulted in relief of pain
symptoms before; it will do it again.”). But for
beliefs about a drug the patient has not taken
before, there will be other factors, such as commu-
nication from the physician (“My doctor indicated
that this drug will work better than aspirin in reliev-
ing my headaches.”), from other people (“This drug
has worked really well for my spouse in relieving
his/her pain symptoms.”), from advertising (“They
claim to have relieved headaches in four of ﬁve
patients.”), from experiences with medications in
general (“Drugs never seem to work for me.”), and
so on. Note that these beliefs about the impact of
taking the drug are expectations that are subject to
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change as new information is received and proc-
essed by the patient. In addition, disease and treat-
ment history will have an inﬂuence on forming
expectations, as described later in the article.
With respect to the relationship of satisfaction to
adherence, the TRA model states that the best pre-
dictor of behavior (i.e., adherence) is the intention
to engage in that behavior. The attitude toward tak-
ing the medication—satisfaction—is only one of the
elements that are predictive of intention. The sec-
ond determinant of behavioral intention is the sub-
jective norm that a person has about engaging in the
behavior. The subjective norm is determined by two
components—the person’s normative belief as to
whether important referent individuals (e.g., pri-
mary physician, spouse, friends) want the person to
adhere to their prescription regimen, weighted by
the person’s motivation to comply with each of
these referent individuals.
What are some of the implications of this model
for research in satisfaction with medication? We
believe the most important insight provided by TRA
is the recognition that satisfaction with medica-
tion is based on the beliefs of the patient about the
likely outcomes of taking the medications and
the patient’s evaluations of these outcomes. Most
research in TRA starts with ascertaining salient
beliefs “from the subject’s perspective.” Therefore,
TRA guides us to assure that we capture all salient
aspects of impacts of taking the medication as
viewed by the patient. Hence, it is important that
great care is taken in assuring that the medication-
related outcomes that the patient is asked to evalu-
ate contain no major errors of omission. In the
extreme, this would lead to each patient generating
his or her own list of salient beliefs and outcomes
associated with taking a drug, as well as the value
placed on each of these, resulting in satisfaction
being determined in a completely idiosyncratic
manner. Nevertheless, as in most research in
patient-reported outcomes, there are measurable
domains of medication-related outcomes that are
common to most patients and for most drugs, as
discussed later in this article.
A second implication of TRA is that although the
behavior of taking the medication can be predicted
by the patient’s intention to take the medication,
this relationship is less than perfect. TRA assumes
that the patient is a rational decision maker; the
patient actively decides whether or not to rigorously
adhere to the prescription regimen. Nevertheless,
not all behavior stems directly from conscious rea-
soning. For example, patients sometimes forget to
take their medication—this is not a conscious deci-
sion on their part. Similarly, the notion of reasoned
action may be problematic for some psychiatric ill-
nesses and, indeed, compliance with psychotropic
drugs is generally poor [54–57]. Hence, TRA shows
us that although assessment of patient satisfaction
with medication can help to better understand pre-
scription adherence, it will not always fully explain
it (i.e., assessment of satisfaction is necessary but
not sufﬁcient for understanding patient adherence).
A third implication of the TRA model focuses
more on the issue of adherence than on the patient
satisfaction. According to the TRA, the normative
component involving motivation to comply with
others is another potential predictor of adherence.
This helps us to place into perspective the literature
on the relation between physician communication
styles and patient adherence [20]. Speciﬁcally, from
the perspective of TRA, it is likely that the physician
would almost always be a salient referent individ-
ual; friends, spouse, etc., are likely to be other sali-
ent referent individuals. It could well be that, in
addition to inﬂuencing a patient’s expectations, as
shown in Figure 2, physician communication styles
may inﬂuence the patient’s motivation to comply
and impact adherence through that route. Note that
this is completely independent of satisfaction with
medication.
Finally, inherent in the TRA model is the focus
on matching the behavior of interest to the level of
speciﬁcity of the underlying beliefs and values that
form the basis of inquiry. If the speciﬁc behavior of
interest is taking one’s medication, then the level of
inquiry should be with respect to the beliefs (i.e.,
expectations) about the outcomes associated with
taking the medication and the value placed on those
outcomes. This is consistent with Figure 1. If our
interest is in a speciﬁc medication, we should focus
our inquiry on satisfaction with that medication
and not on the more general satisfaction with the
treatment and its context or on the health system in
general.
Domains of  Satisfaction
As described above, TRA leads us to the importance
of understanding important outcomes of medica-
tion from the perspective of the patient. The out-
comes in any particular study involving satisfaction
with medication research should be disease and
medication speciﬁc. Nevertheless, for many re-
search applications, these speciﬁc outcomes will fall
into one of the following domains:
Symptom Relief/Efﬁcacy Patients are taking medi-
cations to relieve symptoms and to achieve cure of
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disease, if possible. Therefore, one major domain of
satisfaction involves the extent to which the medi-
cation is efﬁcacious and provides symptom relief.
Although it is possible to inquire about overall
symptom relief and/or efﬁcacy, the more precise
assessment tools will inquire about satisfaction with
relief of speciﬁc symptoms (e.g., itching and tearing
for allergy medications, ear pain for otitis externa
medications [8]). In addition, the questionnaire will
often assess satisfaction with the time until symp-
tom relief (i.e., onset of action, extent of effect, and
duration of effect). The speciﬁc symptoms and
aspects of symptom relief that are actually included
in the satisfaction questionnaire must be based on
patient input. This is discussed in more detail later.
For most diseases and medications, we would
expect efﬁcacy—the degree to which the drug
results in cure and/or symptom relief—to be the
most important determinant of satisfaction with
medication. Nevertheless, satisfaction research is
often invoked when there are trade-offs involved
between competing drugs (e.g., one drug may be
quicker acting but has a less favorable side effect
proﬁle). Or one drug may result in quicker onset of
relief, but another drug may result in greater dura-
tion of relief. Or one drug may have a much more
convenient dosing schedule or mode of administra-
tion than a comparator. These are the very types of
situations in which a manufacturer might wish to
assess patient satisfaction studies. It is much less
likely that satisfaction research would be invoked
when these types of trade-offs are not involved.
Side Effects For some drugs and for some patients,
the cure might be seen as “worse than the disease.”
Satisfaction with the side effects of a medication
and degree of satisfaction/dissatisfaction with these
side effects should be assessed in the questionnaire.
The speciﬁc side effects about which satisfaction
data are obtained should be based on the known
side effects of the drug and also based on patient
input. The issue of the impact of side effects on sat-
isfaction with medication is likely to be most salient
when comparing drugs of approximate equivalent
clinical efﬁcacy, but with different side effect pro-
ﬁles. In addition, as discussed later, the saliency of
side effects can change over the course of the pre-
scription (e.g., side effects early on during the
course of treatment may be less important than
side-effects later in the treatment).
Ease and Convenience Frequently, newer formula-
tions of drugs will compete on the basis of ease and
convenience to the consumer. Aspects of ease and
convenience include dosing schedule; mode of
administration (e.g., pill, liquid, injection, patch,
inhaler), restrictions associated with the medica-
tions (e.g., with meals, avoidance of certain foods),
and product-speciﬁc designs (e.g., portability of cer-
tain devices, operation of devices). As with side
effects, the saliency of ease and convenience factors
is likely to be greatest when comparing medications
of approximately equal clinical efﬁcacy.
Impact on HRQL From a patient’s perspective, one
of the key reasons for treating an illness and seeking
symptom relief through medication is to return to a
normal (i.e., predisease) state of HRQL or, in the
case of chronic conditions, to attenuate the impact
of the indication on HRQL. Hence, in addition to
assessing the impact of a treatment on a patient’s
HRQL, we can also assess the patient’s satisfaction
with that impact. In fact, Shikiar et al. [8] found
that the single best item correlating with overall sat-
isfaction with a medication for otitis externa was an
item dealing with satisfaction with time to return to
normal activities.
As in the case with the other domains of satis-
faction, it is important that the HRQL domains
about which satisfaction of the impacts of medica-
tion are to be obtained should be speciﬁc to the dis-
ease–drug combination (e.g., it may not be worth
the effort to ask about bodily pain if neither the dis-
ease nor the medication involves bodily pain) and
also be based upon salient HRQL dimensions from
the patient’s perspective.
Overall or General Satisfaction In addition to the
speciﬁc domains about which satisfaction might be
obtained, it is frequently useful to include a few
questions dealing with overall satisfaction. Exam-
ples of questions dealing with overall satisfaction
include: “How satisﬁed are you with your medica-
tion?”; “How likely are you to recommend this
medication to a friend who had the same disease?”;
and “Would you ask your doctor to prescribe this
medication in the future if you suffer from this dis-
ease again?” Having several items that assess over-
all satisfaction allows the researcher to compare this
overall satisfaction with satisfaction with symptom
relief, with side effects, with impacts on HRQL,
with ease and convenience, etc. Analyses involving
the different domains of satisfaction allow the
researcher to understand the key drivers underlying
satisfaction with the particular drug.
Additional Domains Any given patient satisfaction
research program may result in program-speciﬁc
domains that are relevant to the speciﬁc disease,
drug, and/or comparator. For example, in some sit-
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uations involving a new device, questions might be
asked about the patient’s conﬁdence in using the
device. In other instances, satisfaction with the
information provided about the drug—by the pack-
age insert, the physician, the pharmacist, and/or the
nurse—might be deemed important to ascertain, or
ease of storage of the drug or device might be salient
in some instances. In their review of the satisfaction
literature, Weaver and colleagues [10] list 17 differ-
ent topic areas that had been used in at least two
studies.
Developing Psychometrically Sound 
Satisfaction Instruments
Item Generation
Generating a satisfaction instrument entails gather-
ing information from different sources. One source
of information is the published literature on the
disease and its treatment, including the clinical
trial literature. Patient involvement is essential to
develop an initial item list and assist with reﬁne-
ments of the questionnaire. Using any one or more
of patient elicitation techniques (e.g., focus groups,
structured interviews, open-ended interviews), the
researcher should ascertain the most salient aspects
of taking the medication from the patient perspec-
tive. Physicians who have broad experience in treat-
ing the disease and use of medications for the
disease will be able to identify and/or clarify issues
raised by patients. Finally, it is good practice to
pilot test the draft instrument with a group of
patients then query them as to their interpretations
of each item. This “cognitive debrieﬁng” will result
in deletions, additions, and modiﬁcations to the
draft instrument.
Framing the Questions
Streiner and Norman [58] describe biases common
to most questionnaires, as well as strategies for min-
imizing its impact on the responses given to the
questionnaire. In addition, several researchers have
discussed the prevalence of acquiescent response
bias (ARB) or social desirability response set
(SDRS) within satisfaction-with-care studies
[14,59].
Psychometric Analyses
The psychometric properties of the instrument
should be established, including its reliability, valid-
ity, and sensitivity, depending on the actual research
design. Standards and guidelines exist for evaluat-
ing reliability and validity of various patient-
assessed instruments [60–63].
Additional Issues for Consideration
Potential Transitory Nature of  Satisfaction
The beliefs and values underlying satisfaction may
change over time. When this occurs owing to adap-
tation to an illness, it is referred to as “response
shift.” Response shift may also occur owing to a
patient’s change in internal standard of measure-
ment or a personal redeﬁnition of satisfaction
[64,65]. For example, over the course of the treat-
ment regimen, as symptoms of a disease subside, a
drug’s side effects or lifestyle limitations may
become more prominent and the actual disease
symptoms may become less important. To the
extent this results in changes in satisfaction with the
medication, this might help explain a decrease in
adherence over time. Therefore, appropriate meas-
urement of satisfaction with medication requires
long-term and/or repeated observations. Addition-
ally, it may be necessary to actually measure
whether a patient’s beliefs or values have changed
over time, actually taking into account the response
shift [64,65].
Another aspect of the transitory nature of satis-
faction is that expectations about a medication are
formed in part by disease and treatment history.
Dawson et al. [66] recently explored the paradox
of patients expressing satisfaction with inadequate
pain management. They demonstrated that satis-
faction was related to the patient’s expectations
about pain and its inevitability, and they point
toward improving patient–provider relationships
to help shape patient expectations about pain man-
agement. Of course, the physician is not the only
source of information that may shape patients’
expectations. Increased DTC advertising over the
past decade has likely changed consumer expecta-
tions about the efﬁcacy of many medications.
Finally, the relationship between expectations and
satisfaction has been demonstrated in the realm of
satisfaction with medical care [67–69]; as more
research is performed in the area of satisfaction
with medication, we would expect similar ﬁndings
to appear.
Patient History and Other Characteristics
Related to the notion of expectations is the differ-
ence between patients with long-term chronic ill-
nesses who have tried a variety of therapies versus
ﬁrst-time medication users. The former might have
very different expectations about a new drug than
the latter, and so might be much more satisﬁed with
an incremental improvement in outcomes, whereas
the latter might be disappointed in a small improve-
Satisfaction with Medication 213
ment. In performing satisfaction research, it is
important to take into account patients’ back-
grounds, especially disease history. These differ-
ences might be handled statistically, but if they are
not assessed, they cannot be taken into account in
any analyses.
Patient Satisfaction Claims: 
Regulatory Implications
Because patient satisfaction is a patient reported
outcome, it would stand to reason that the require-
ments for making claims on other patient-reported
claims would have relevance to satisfaction with
medication. Leidy et al. [31] discussed in detail rec-
ommendations for evaluating the validity of quality
of life claims for labeling and promotion. In short,
they recommended:
• Assurance that all relevant domains are
included—this translates to the content validity
evidence for the instrument. Having patient
feedback as an integral part of instrument
development is very important in establishing
the relevancy and content-coverage of domains
of satisfaction.
• A well-documented rationale for including the
domains—for example, it should be clear why
satisfaction with ease and convenience with
respect to a medication under study was
included in the study.
• Evidence of instrument reliability and valid-
ity—thorough and appropriate psychometric
analyses will provide the requisite evidence.
• Clear objective and hypotheses—the satisfac-
tion claim should not be the result of a “ﬁsh-
ing expedition.” Studies should be based on
the expected advantage of one drug over an
appropriate comparator, and the statistical
hypotheses and delineation of primary and
secondary outcomes should reﬂect these
expectations.
• Adequate sample size—the study should be
appropriately powered. In fact, the FDA will
frequently want to see the results from more
than a single, well-constructed study.
• Careful implementation—the studies developed
to assess differences in satisfaction should
undergo the same rigor as other clinical studies
that will be used to make clinical claims.
• Complete disclosure of all results—in accord
with the statistical plan, all outcome measures,
both primary and secondary, should be
reported.
Summary and Conclusions
Patient satisfaction with medication is a potentially
important patient-reported outcome. There is rea-
son to believe that it is an important factor linked to
adherence with medications, which has been repeat-
edly a major concern in health care [27,28,70–72].
Satisfaction has been all too often taken lightly as
an outcome measure. When it is collected in clinical
trials, it has often been as a single, untested item.
Nevertheless, just as the inclusion of HRQL in
clinical trials and other medication research has
resulted in a more scientiﬁc, methodologic ap-
proach to its assessment over the past two decades,
if patient satisfaction with medication is to be
treated as the important outcome measure that we
believe it is in many situations, then the ﬁeld should
be subject to similar, rigorous methodologic stand-
ards.
We recognize the efforts of the members of MEDTAP’s
Centers for Health Outcomes Research and Dennis Rev-
icki and Karin Coyne for their careful reviews of early
drafts for the manuscript.
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